F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES

Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act

(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2026 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization

(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness

(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness